CRISPR Therapeutics CRSP Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $423.31M+80.0% | $347.56M+16.5% | $286.5M+27.0% | $193.62M-60.0% | $235.18M-66.8% | ||
| $2.02B+24.6% | $1.63B+1.4% | $1.63B-4.7% | $1.53B+0.7% | $1.62B+15.7% | ||
| $7.63M-4.7% | $7.63M-33.8% | $8.01M-30.5% | $8.01M-30.5% | $8.01M-30.5% | ||
| -$0— | $0-100% | $0— | $0— | $0— | ||
| $6.58M-46.6% | $9.84M+18.5% | $13.38M+62.3% | $12.43M+41.4% | $12.33M+7.2% | ||
| $2.45B+31.1% | $1.99B+2.5% | $1.93B-0.8% | $1.73B-13.8% | $1.87B-11.9% | ||
| $112.18M-13.3% | $115.85M-13.6% | $120.83M-12.8% | $124.93M-12.7% | $129.43M-12.1% | ||
| $128.67M-8.3% | $131.72M-8.2% | $134.66M-7.9% | $137.64M-7.3% | $140.28M-7.3% | ||
| $28.98M+39.5% | $24.37M+53.9% | $24.31M+53.0% | $25.47M+68.2% | $20.78M+122% | ||
| $2.73B+25.8% | $2.27B+1.0% | $2.25B-0.5% | $2.03B-13.3% | $2.17B-11.2% | ||
| $13.65M+4.5% | $11.14M-24.3% | $11.8M-24.3% | $9.75M+3.2% | $13.06M-20.6% | ||
| $13.11M— | $13.11M+25.9% | $0-100% | $0-100% | $0-100% | ||
| $15.34M+408% | $15.77M+310% | $1.3M-71.1% | $2.13M-55.3% | $3.02M-25.8% | ||
| $18.61M+6.3% | $18.58M+7.5% | $18.26M+8.1% | $18.03M+9.6% | $17.51M+9.5% | ||
| $638K-48.6% | $1.11M+147% | $3.43M+309% | $715K+57.5% | $1.24M+2.8% | ||
| $136.29M+14.1% | $149.12M+69.9% | $118.96M+32.5% | $104.36M-18.4% | $119.45M+0.4% | ||
| $585.47M— | $0— | —— | —— | —— | ||
| $183.56M-9.1% | $188.17M-8.8% | $192.77M-8.5% | $197.43M-8.1% | $201.85M-7.8% | ||
| $5.95M+79.2% | $6.14M+78.3% | $5.28M+43.5% | $4.48M+22.8% | $3.32M-8.2% | ||
| $911.26M+170% | $343.43M+10.8% | $329.33M+4.1% | $318.59M-11.2% | $336.94M-5.1% | ||
| $3.12M+14.5% | $3.09M+14.4% | $3.01M+12.3% | $2.79M+4.8% | $2.72M+2.4% | ||
| $3.88B+16.8% | $3.86B+17.2% | $3.72B+14.4% | $3.41B+5.9% | $3.32B+3.9% | ||
| -$2.07B-37.9% | -$1.95B-42.6% | -$1.82B-36.8% | -$1.71B-37.6% | -$1.5B-34.5% | ||
| -$1.94M-147% | $4.82M+162% | $4.99M-52.8% | $4.04M+240% | $4.14M+366% | ||
| $60K-3.2% | $60K-3.2% | $60K-3.2% | $62K0.0% | $62K0.0% | ||
| $1.81B-0.8% | $1.92B-0.5% | $1.92B-1.2% | $1.71B-13.6% | $1.83B-12.2% | ||
| $2.73B+25.8% | $2.27B+1.0% | $2.25B-0.5% | $2.03B-13.3% | $2.17B-11.2% | ||
| $2.02B+24.6% | $1.63B+1.4% | $1.63B-4.7% | $1.53B+0.7% | $1.62B+15.7% | ||
| $28.98M+39.5% | $24.37M+53.9% | $24.31M+53.0% | $25.47M+68.2% | $20.78M+122% | ||
| $128.67M-8.3% | $131.72M-8.2% | $134.66M-7.9% | $137.64M-7.3% | $140.28M-7.3% | ||
| $128.67M-8.3% | $131.72M-8.2% | $134.66M-7.9% | $137.64M-7.3% | $140.28M-7.3% | ||
| $28.98M+39.5% | $24.37M+53.9% | $24.31M+53.0% | $25.47M+68.2% | $20.78M+122% | ||
| $128.67M-8.3% | $131.72M-8.2% | $134.66M-7.9% | $137.64M-7.3% | $140.28M-7.3% | ||
| $28.98M+39.5% | $24.37M+53.9% | $24.31M+53.0% | $25.47M+68.2% | $20.78M+122% | ||
| $74.93M-11.4% | $89.41M+118% | $84.18M+78.3% | $73.74M-19.7% | $84.62M+10.7% | ||
| $74.93M-11.4% | $89.41M+118% | $84.18M+78.3% | $73.74M-19.7% | $84.62M+10.7% | ||
| $13.11M— | $13.11M+25.9% | $0-100% | $0-100% | $0-100% | ||
| $787.64M+259% | $206.75M-7.6% | $211.02M-7.3% | $215.45M-6.9% | $219.36M-6.6% | ||
| $3.88B+16.8% | $3.86B+17.2% | $3.72B+14.4% | $3.41B+5.9% | $3.32B+3.9% | ||
| $3.12M+14.5% | $3.09M+14.4% | $3.01M+12.3% | $2.79M+4.8% | $2.72M+2.4% | ||
| $60K-3.2% | $60K-3.2% | $60K-3.2% | $62K0.0% | $62K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are CRISPR Therapeutics's total assets?
- CRISPR Therapeutics (CRSP) holds $2.7B in total assets, up 25.8% year over year.
- How much debt does CRISPR Therapeutics have?
- CRISPR Therapeutics carries $787.6M in total debt against $1.8B of shareholders' equity, a debt-to-equity ratio of 0.43.
- How much cash does CRISPR Therapeutics have?
- CRISPR Therapeutics holds $423.3M in cash and equivalents.
- Can CRISPR Therapeutics cover its short-term obligations?
- Its current ratio is 17.96 — current assets exceed current liabilities.
- Where does CRISPR Therapeutics's balance sheet data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
